This Article  • References  • Full text PDF  • Correction  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Jeffrey M. Hoeg, MD; Richard E. Gregg, MD; H. Bryan Brewer, Jr, MD

JAMA. 1986;255(4):512-521.

Abstract
Recent clinical trials indicate that reduction of plasma cholesterol concentrations in individuals with increased levels of low-density lipoproteins reduces their risk of myocardial infarction and death. Therefore, the question of "whether to treat" should be shifted to "whom to treat" and "how best to treat." The understanding of normal lipid transport via the plasma lipoproteins has grown to a sophisticated level over the past 20 years. Plasma cholesterol, required for cellular membrane integrity, and plasma triglycerides, the primary mammalian energy source, are carried in lipoprotein particles that vary in size, density, lipid composition, and apolipoprotein content. Some lipoprotein particles (low-density lipoproteins) play a causal role in the atherosclerotic process, while other particles (high-density lipoproteins) appear to prevent this process. Utilizing this understanding of the plasma lipoproteins, a systematic approach to the management of the patient with hyperlipoproteinemia has been developed which may lead to the normalization of plasma lipoprotein concentrations in the majority of hyperlipoproteinemic patients.

(JAMA 1986;255:512-521)

Author Affiliations
From the Molecular Disease Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, Md.

Footnotes
Reprint requests to National Institutes of Health, Bldg 10, Room 7N114, 9000 Rockville Pike, Bethesda, MD 20205 (Dr Hoeg).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Combination Drug Therapy for Hypercholesterolemia: The Trade-off Between Cost and Simplicity
Heudebert et al.
Arch Intern Med 1993;153:1828-1837.
ABSTRACT  

Lipoprotein(a) Clinical Approach to a Unique Atherogenic Lipoprotein
Rader and Brewer
JAMA 1992;267:1109-1112.
ABSTRACT  

Comparative Study of a Microporous Cholestyramine Analogue (Filicol) and Gemfibrozil for Treatment of Severe Primary Hypercholesterolemia: Short- and Long-term Results
Ros et al.
Arch Intern Med 1991;151:301-305.
ABSTRACT  

Effect of Low-Dose Niacin on High-Density Lipoprotein Cholesterol and Total Cholesterol/High-Density Lipoprotein Cholesterol Ratio
Luria
Arch Intern Med 1988;148:2493-2495.
ABSTRACT  

Cutting Into Cholesterol: Cost-effective AlternatiCost-effective Treating Hypercholesterolemia
Kinosian and Eisenberg
JAMA 1988;259:2249-2254.
ABSTRACT  

Report of the National Cholesterol Education Program Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults
The Expert Panel et al.
Arch Intern Med 1988;148:36-69.
ABSTRACT  

3-Hydroxy-3-Methylglutaryl--Coenzyme A Reductase Inhibitors in the Treatment of Hypercholesterolemia
Hoeg and Brewer
JAMA 1987;258:3532-3536.
ABSTRACT  

Statement on Hypertension in Diabetes Mellitus: Final Report
The Working Group on Hypertension in Diabetes
Arch Intern Med 1987;147:830-842.
ABSTRACT  

Cholesterol Reduction and Life Expectancy: A Model Incorporating Multiple Risk Factors
TAYLOR et al.
ANN INTERN MED 1987;106:605-614.
ABSTRACT  

The Method of Determination Must Be Considered in Interpreting Blood Cholesterol Levels
Blank et al.
JAMA 1986;256:2867-2870.
ABSTRACT  

Cholesterol and Children
Barness
JAMA 1986;256:2871-2871.
ABSTRACT  

The Management of Hyperlipoproteinemia
Norenberg
JAMA 1986;256:1003-1003.
ABSTRACT  

The Management of Hyperlipoproteinemia
Gaudet
JAMA 1986;255:2895-2895.
ABSTRACT